Compare BCSF & MGTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | BCSF | MGTX |
|---|---|---|
| Founded | 2015 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Finance/Investors Services | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 838.7M | 909.1M |
| IPO Year | 2015 | 2018 |
| Metric | BCSF | MGTX |
|---|---|---|
| Price | $12.20 | $11.71 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 2 | 7 |
| Target Price | $14.00 | ★ $24.57 |
| AVG Volume (30 Days) | 386.0K | ★ 780.8K |
| Earning Date | 05-11-2026 | 05-12-2026 |
| Dividend Yield | ★ 14.61% | N/A |
| EPS Growth | N/A | ★ 33.02 |
| EPS | ★ 0.05 | N/A |
| Revenue | N/A | ★ $81,391,000.00 |
| Revenue This Year | N/A | $141.38 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $240.80 | ★ N/A |
| Revenue Growth | N/A | ★ 144.57 |
| 52 Week Low | $11.82 | $6.31 |
| 52 Week High | $15.84 | $12.28 |
| Indicator | BCSF | MGTX |
|---|---|---|
| Relative Strength Index (RSI) | 37.21 | 69.21 |
| Support Level | $11.92 | $7.10 |
| Resistance Level | $13.74 | $11.85 |
| Average True Range (ATR) | 0.30 | 0.63 |
| MACD | -0.06 | 0.22 |
| Stochastic Oscillator | 27.79 | 83.63 |
Bain Capital Specialty Finance Inc is an externally managed, closed-end, non-diversified management investment company. The company's objective is to provide risk-adjusted returns and current income to investors by investing in middle-market companies. Its portfolio of investments includes First Lien Senior Secured Loan, Preferred Equity, Equity Interest, Warrants, and Second Lien Senior Secured Loan, and others.
MeiraGTx Holdings PLC is a vertically integrated, clinical-stage genetic medicines company focused on developing targeted therapies for diseases with high unmet need, including radiation-induced xerostomia, Parkinson's disease, and AIPL1-associated retinal dystrophy. The company's pipeline is supported by end-to-end in-house manufacturing capabilities, including GMP viral vector production, plasmid manufacturing, and quality control, enabling development from IND to commercial supply. It also utilizes proprietary platforms in viral vector optimization and riboswitch-based gene regulation to enhance efficacy and reduce dosage. The company operates in the United States, the United Kingdom, and the European Union.